재생의료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for regenerative medicine. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global regenerative medicine market from 2024 to 2031.

Key Insights:

• Regenerative Medicine Market Size (2024E): US$32.3 Mn
• Projected Market Value (2031F): US$109.4 Mn
• Global Market Growth Rate (CAGR 2024 to 2031):19.1%

Regenerative Medicine Market - Report Scope:

Regenerative medicine encompasses various therapeutic approaches aimed at repairing, replacing, or regenerating damaged tissues and organs to restore normal function. This market includes stem cell therapy, tissue engineering, gene therapy, and other innovative techniques. Regenerative medicine has the potential to address a range of medical conditions, including chronic diseases, injuries, and age-related disorders, making it a crucial area of research and development in the healthcare sector. The market caters to hospitals, research institutions, and biopharmaceutical companies, offering a diverse array of therapies and products.

Market Growth Drivers:

The global regenerative medicine market is propelled by several key factors, including an increasing prevalence of chronic diseases, advancements in stem cell research, and rising investments in biotechnology and healthcare infrastructure. The growing awareness of regenerative therapies as viable treatment options for conditions such as diabetes, cardiovascular diseases, and neurodegenerative disorders further drives market expansion. Additionally, the increasing number of clinical trials and the commercialization of innovative therapies contribute to the growing acceptance and demand for regenerative medicine solutions.

Market Restraints:

Despite promising growth prospects, the regenerative medicine market faces challenges related to regulatory hurdles, high development costs, and ethical concerns surrounding stem cell research. Stringent regulations governing the approval and commercialization of regenerative therapies can delay market entry and increase operational costs for manufacturers. Moreover, the complexity and high costs associated with developing regenerative medicine products may hinder accessibility, particularly in emerging economies with limited healthcare resources. Addressing these challenges requires collaboration between industry stakeholders, regulatory bodies, and policymakers to establish clear guidelines and promote equitable access to regenerative therapies.

Market Opportunities:

The regenerative medicine market presents significant growth opportunities driven by technological advancements, increasing healthcare expenditure, and evolving patient-centric approaches. Innovations in gene editing technologies, such as CRISPR, and the development of bioprinting techniques enhance the potential for personalized regenerative therapies. Furthermore, the growing focus on regenerative medicine applications in areas such as orthopedics, oncology, and wound healing expands market scope and stimulates research and development efforts. Strategic partnerships, investment in clinical trials, and the introduction of cost-effective regenerative solutions are essential to capitalize on emerging opportunities and sustain market leadership in this dynamic field.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the regenerative medicine market globally?
• Which therapeutic areas and applications are seeing increased adoption of regenerative medicine?
• How are technological advancements reshaping the competitive landscape of the regenerative medicine market?
• Who are the key players contributing to the regenerative medicine market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global regenerative medicine market?

Competitive Intelligence and Business Strategy:

Leading players in the global regenerative medicine market, including Amgen Inc., Gilead Sciences, Inc., and Regenative Labs, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest heavily in research and development to create advanced regenerative therapies, including cell-based treatments and tissue engineering products, catering to diverse patient needs. Collaborations with research institutions, healthcare providers, and regulatory agencies facilitate market access and promote technology adoption. Additionally, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving regenerative medicine landscape.

Key Companies Profiled:

• AstraZeneca plc
• F. Hoffmann-La Roche Ltd.
• Integra Lifesciences Corp.
• Astellas Pharma, Inc.
• Cook Biotech, Inc.
• Bayer AG
• Pfizer, Inc.
• Merck KGaA
• Abbott
• Vericel Corp.
• Novartis AG
• GlaxoSmithKline (GSK)

Regenerative Medicine Market Segmentation

By Product Type

• Cell Therapy
• Gene Therapy
• Cell-Based Immunotherapy
• Tissue Engineering

By Application

• Orthopaedics
• Wound Care
• Oncology
• Rare Diseases

By End User

• Hospitals
• Clinics

By Region

• North America
• Europe
• East Asia
• South Asia & Pacific
• Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Regenerative Medicine Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Technology Assessment
• 3.3. Regulatory Landscape
• 3.4. Value Chain Analysis
  • 3.4.1. List of Distribution Channel/Marketplaces
    • 3.4.1.1. Retail
    • 3.4.1.2. Audiology
    • 3.4.1.3. E-Commerce
  • 3.4.2. List of End User (Industry)
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Regenerative Medicine Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024-2031
• 4.3. Global Regenerative Medicine Market Outlook: Drug Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Type, 2019-2023
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
    • 4.3.3.1. Antiplatelet Agents
    • 4.3.3.2. Glycoprotein IIb/IIIa Inhibitors
    • 4.3.3.3. Antithrombotic Agents
    • 4.3.3.4. Beta-adrenergic Blockers
• 4.4. Market Attractiveness Analysis: Drug Type
• 4.5. Global Regenerative Medicine Market Outlook: Route of Administration
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2019-2023
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
    • 4.5.3.1. Oral
    • 4.5.3.2. Injectable
• 4.6. Market Attractiveness Analysis: Route of Administration
• 4.7. Global Regenerative Medicine Market Outlook: Distribution Channel
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
  • 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
    • 4.7.3.1. Hospitals
    • 4.7.3.2. Clinics
    • 4.7.3.3. Retail Pharmacies
    • 4.7.3.4. Online Pharmacies
• 4.8. Market Attractiveness Analysis: Distribution Channel

5. Global Regenerative Medicine Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Regenerative Medicine Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 6.3.1. By Country
  • 6.3.2. By Drug Type
  • 6.3.3. By Route of Administration
  • 6.3.4. By Distribution Channel
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 6.4.1. U.S.
  • 6.4.2. Canada
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 6.5.1. Antiplatelet Agents
  • 6.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 6.5.3. Antithrombotic Agents
  • 6.5.4. Beta-adrenergic Blockers
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 6.6.1. Oral
  • 6.6.2. Injectable
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 6.7.1. Hospitals
  • 6.7.2. Clinics
  • 6.7.3. Retail Pharmacies
  • 6.7.4. Online Pharmacies
• 6.8. Market Attractiveness Analysis

7. Europe Regenerative Medicine Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 7.3.1. By Country
  • 7.3.2. By Drug Type
  • 7.3.3. By Route of Administration
  • 7.3.4. By Distribution Channel
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. U.K.
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Russia
  • 7.4.7. Turkiye
  • 7.4.8. Rest of Europe
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 7.5.1. Antiplatelet Agents
  • 7.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 7.5.3. Antithrombotic Agents
  • 7.5.4. Beta-adrenergic Blockers
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 7.6.1. Oral
  • 7.6.2. Injectable
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 7.7.1. Hospitals
  • 7.7.2. Clinics
  • 7.7.3. Retail Pharmacies
  • 7.7.4. Online Pharmacies
• 7.8. Market Attractiveness Analysis

8. East Asia Regenerative Medicine Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 8.3.1. By Country
  • 8.3.2. By Drug Type
  • 8.3.3. By Route of Administration
  • 8.3.4. By Distribution Channel
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. South Korea
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 8.5.1. Antiplatelet Agents
  • 8.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 8.5.3. Antithrombotic Agents
  • 8.5.4. Beta-adrenergic Blockers
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 8.6.1. Oral
  • 8.6.2. Injectable
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 8.7.1. Hospitals
  • 8.7.2. Clinics
  • 8.7.3. Retail Pharmacies
  • 8.7.4. Online Pharmacies
• 8.8. Market Attractiveness Analysis

9. South Asia and Oceania Regenerative Medicine Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 9.3.1. By Country
  • 9.3.2. By Drug Type
  • 9.3.3. By Route of Administration
  • 9.3.4. By Distribution Channel
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 9.4.1. India
  • 9.4.2. Southeast Asia
  • 9.4.3. ANZ
  • 9.4.4. Rest of South Asia & Oceania
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 9.5.1. Antiplatelet Agents
  • 9.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 9.5.3. Antithrombotic Agents
  • 9.5.4. Beta-adrenergic Blockers
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 9.6.1. Oral
  • 9.6.2. Injectable
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 9.7.1. Hospitals
  • 9.7.2. Clinics
  • 9.7.3. Retail Pharmacies
  • 9.7.4. Online Pharmacies
• 9.8. Market Attractiveness Analysis

10. Latin America Regenerative Medicine Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 10.3.1. By Country
  • 10.3.2. By Drug Type
  • 10.3.3. By Route of Administration
  • 10.3.4. By Distribution Channel
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 10.4.1. Brazil
  • 10.4.2. Mexico
  • 10.4.3. Rest of Latin America
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 10.5.1. Antiplatelet Agents
  • 10.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 10.5.3. Antithrombotic Agents
  • 10.5.4. Beta-adrenergic Blockers
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 10.6.1. Oral
  • 10.6.2. Injectable
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 10.7.1. Hospitals
  • 10.7.2. Clinics
  • 10.7.3. Retail Pharmacies
  • 10.7.4. Online Pharmacies
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Regenerative Medicine Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Pricing Analysis
• 11.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 11.3.1. By Country
  • 11.3.2. By Drug Type
  • 11.3.3. By Route of Administration
  • 11.3.4. By Distribution Channel
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 11.4.1. GCC Countries
  • 11.4.2. Egypt
  • 11.4.3. South Africa
  • 11.4.4. Northern Africa
  • 11.4.5. Rest of Middle East & Africa
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 11.5.1. Antiplatelet Agents
  • 11.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 11.5.3. Antithrombotic Agents
  • 11.5.4. Beta-adrenergic Blockers
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 11.6.1. Oral
  • 11.6.2. Injectable
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 11.7.1. Hospitals
  • 11.7.2. Clinics
  • 11.7.3. Retail Pharmacies
  • 11.7.4. Online Pharmacies
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Bayer HealthCare LLC
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Boehringer Ingelheim International GmbH
    • 12.3.2.1. Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Eli Lilly and Company
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. Janssen Biotech, Inc.
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Merck & Co. Inc.
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. Novartis International AG
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. Sanofi
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. AstraZeneca
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. Pfizer
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. Amgen, Inc
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. GlaxoSmithKline PLC
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. Regeneron Pharmaceuticals Inc.
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Bristol-Myers Squibb Company
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations